Skip to main content

Advertisement

Fig. 1 | Clinical and Translational Allergy

Fig. 1

From: Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT

Fig. 1

AIT timeline and study design. Subcutaneous immunotherapy with birch pollen extract was performed with 11–13 injections at intervals of 1–2 weeks during the updosing phase. After reaching the maintenance dose, injections were further administered every 4–8 weeks until 52 weeks. Serum samples were obtained before treatment (T0), 2 weeks after reaching maintenance dose (T1), and 1 year after starting treatment (T2). At the same time points, NPT were performed and RTSS were noted

Back to article page